Negotiating excess treatment costs in a clinical research trial: the good, the bad and the innovative

Trials. 2016 Feb 9:17:71. doi: 10.1186/s13063-016-1208-5.

Abstract

Barriers to recovering the excess treatment costs associated with health research from local organisations in the United Kingdom can increase research costs, delay completion of high- quality studies and risk disenfranchising health trusts and patients from participation. The authors demonstrate how the process for recovering excess treatment costs at a local National Health Service (NHS) trust level in a multicentre study was inconsistent and resulted in excess effort and cost to the research budget. An innovative example of how an organisation acting as a broker between commissioners and researchers facilitated a more timely excess treatment cost agreement is highlighted.

Trial registration: Current Controlled Trials ISRCTN68798818, registered on 18 February 2014.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomedical Research / economics*
  • Clinical Trials as Topic / economics*
  • Health Care Costs*
  • Humans

Associated data

  • ISRCTN/ISRCTN68798818